Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Christen Lykkegaard Andersen*, Mads Emil Bjørn, Mary Frances McMullin, Claire Harrison, Jan Samuelsson, Elisabeth Ejerblad, Sonja Zweegman, Savio Fernandes, David Bareford, Steven Knapper, Eva Löfvenberg, Olle Linder, Bjørn Andreasson, Erik Ahlstrand, Morten Krogh Jensen, Ole Weis Bjerrum, Hanne Vestergaard, Herdis Larsen, Tobias Wirenfeldt Klausen, Torben Mourits-AndersenVibe Skov, Mads Thomassen, Torben Kruse, Kirsten Grønbæk, Hans Carl Hasselbalch

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<. 0.0001) and 1.7 times higher than in ET (P= 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

OriginalsprogEngelsk
Sider (fra-til)816-821
Antal sider6
TidsskriftLeukemia Research
Vol/bind38
Udgave nummer7
DOI
StatusUdgivet - jul. 2014

Fingeraftryk

Udforsk hvilke forskningsemner 'Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat' indeholder.

Citationsformater